<h2 dir="ltr">IgG4-Related Disease</h2>
<p dir="ltr">IgG4-Related Disease (IgG4-RD) is a rare, chronic, immune-mediated condition characterized by inflammation and fibrosis in one or more organs, often with elevated levels of IgG4-positive plasma cells. It can affect multiple systems including the pancreas, salivary glands, kidneys, lungs, and lymph nodes. Common symptoms vary by organ but may include swelling, pain, and organ dysfunction.</p>
<h2 dir="ltr"><strong>Epidemiology Segmentation</strong></h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total diagnosed prevalent cases of IgG4-RD</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Gender-specific diagnosed prevalent cases of IgG4-RD</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Age-specific diagnosed prevalent cases of IgG4-RD</p>
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/igg4-related-disease-epidemiology-forecast"><strong>IgG4-Related Disease Epidemiology</strong></a></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">In 2024, the diagnosed prevalent cases of IgG4-RD in the 7MM were approximately 148,970.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The US accounted for the highest number, with 56,800 cases.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Gender-specific cases in the US included 39,100 males and 17,700 females.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The EU4 and the UK reported 53,550 cases, with 38,850 in males and 14,750 in females.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">US cases are projected to increase from 2025 to 2034.</p>
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/igg4-related-disease-market"><span style="text-decoration: underline;"><strong>IgG4-Related Disease Market</strong></span></a></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">In 2024, the IgG4-RD market in the 7MM was valued at ~USD 170 million and is projected to grow steadily.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The US led with ~USD 90 million, while the EU4 and UK contributed ~USD 80 million, led by Germany.</p>
</li>
</ul>
<h3 dir="ltr"><strong>IgG4-Related Disease Market Drivers</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Growing awareness among clinicians and improvements in imaging techniques, histopathology, and biomarker testing have led to better recognition and diagnosis of IgG4-RD, boosting early patient identification and market potential.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">An increase in R&amp;D efforts focused on targeted biologics (such as anti-CD20 monoclonal antibodies) and novel immunomodulatory agents is fueling market growth, with multiple companies exploring treatments beyond corticosteroids to address relapse and steroid resistance.</p>
</li>
</ul>
<h3 dir="ltr"><strong>IgG4-Related Disease Market Barriers</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Currently, there are no globally approved therapies specifically indicated for IgG4-RD, leading to off-label use of immunosuppressants and corticosteroids, which limits optimal treatment options and hinders commercial growth.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">IgG4-RD remains a rare and often misdiagnosed condition due to overlapping clinical presentations with other autoimmune or malignant diseases. This underdiagnosis limits the size of the addressable patient pool and impacts clinical trial recruitment.</p>
</li>
</ul>
<h3 dir="ltr"><strong>IgG4-Related Disease Key Therapies</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Obexelimab (XmAb5871)</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Rilzabrutinib (PRN1008/SAR444671)</p>
</li>
</ul>
<p dir="ltr">And others.&nbsp;</p>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/igg4-related-disease-pipeline-insight"><span style="text-decoration: underline;"><strong>IgG4-Related Disease Key Players</strong></span></a></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Zenas BioPharma</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Bristol Myers Squibb</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Amgen</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Sanofi</p>
</li>
</ul>
<p dir="ltr">And others.</p>

IgG4-Related Disease Market

IgG4-Related Disease Infographics

IgG4-Related Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape